This study demonstrates that GFAP-positive astrocyte-specific deletion of GLT1 reduced anxiety- and depression-like behaviors using a comprehensive array of behavioral tests including EPM, TST and FST. This evidence concerns the gene SLC1A2 and depressive symptom measurement.